Characterization of a Library of 20 HBV-specific MHC Class II-restricted T Cell Receptors
Overview
Authors
Affiliations
CD4 T cells play an important role in the immune response against cancer and infectious diseases. However, mechanistic details of their helper function in hepatitis B virus (HBV) infection in particular, or their advantage for adoptive T cell therapy remain poorly understood as experimental and therapeutic tools are missing. Therefore, we identified, cloned, and characterized a comprehensive library of 20 MHC class II-restricted HBV-specific T cell receptors (TCRs) from donors with acute or resolved HBV infection. The TCRs were restricted by nine different MHC II molecules and specific for eight different epitopes derived from intracellularly processed HBV envelope, core, and polymerase proteins. Retroviral transduction resulted in a robust expression of all TCRs on primary T cells. A high functional avidity was measured for all TCRs specific for epitopes S17, S21, S36, and P774 (half-maximal effective concentration [EC] <10 nM), or C61 and preS9 (EC <100 nM). Eight TCRs recognized peptide variants of HBV genotypes A to D. Both CD4 and CD8 T cells transduced with the MHC II-restricted TCRs were polyfunctional, producing interferon (IFN)-γ, tumor necrosis factor (TNF)-α, interleukin (IL)-2, and granzyme B (GrzB), and killed peptide-loaded target cells. Our set of MHC class II-restricted TCRs represents an important tool for elucidating CD4 T cell help in viral infection with potential benefit for T cell therapy.
Bertoletti A, Tan A Clin Mol Hepatol. 2024; 30(4):728-734.
PMID: 38934109 PMC: 11540402. DOI: 10.3350/cmh.2024.0469.
Schreiber S, Dressler L, Loffredo-Verde E, Asen T, Farber S, Wang W Front Immunol. 2024; 15:1340619.
PMID: 38711498 PMC: 11072186. DOI: 10.3389/fimmu.2024.1340619.
Host and HBV Interactions and Their Potential Impact on Clinical Outcomes.
Jose-Abrego A, Roman S, Laguna-Meraz S, Panduro A Pathogens. 2023; 12(9).
PMID: 37764954 PMC: 10535809. DOI: 10.3390/pathogens12091146.
The HLA class-II immunopeptidomes of AAV capsids proteins.
Brito-Sierra C, Lannan M, Siegel R, Malherbe L Front Immunol. 2023; 13:1067399.
PMID: 36605211 PMC: 9807805. DOI: 10.3389/fimmu.2022.1067399.
Debelec-Butuner B, Quitt O, Schreiber S, Momburg F, Wisskirchen K, Protzer U Front Immunol. 2022; 13:1029214.
PMID: 36405686 PMC: 9670976. DOI: 10.3389/fimmu.2022.1029214.